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the restrictive formulary will still always be more costly
than the unrestrictive one. We then allow effectiveness
and costs to vary and derive equation to calculate the
cost of a restrictive formulary in those cases. We derive
the equations for patients with various distributions of
baseline severity. Last, we apply the equations and actual
effectiveness and cost data to the case of atypical anti-
psychotics where Ontario and British Columbia Provin-
cial formularies have mandated that risperidone be pre-
scribed before quetiapine or olanzapine. RESULT: The
cost of the restrictive status would range from $0.87–
0.97 per patient per day with mild symptoms treated
with risperidone, $2.65–3.30 for patients with moderate
symptoms and $5.14–5.73 for patients with severe symp-
toms. The range depends on effectiveness rates. Even if
all drug costs were equal and the efficacy rates were all
80 percent, the cost per patient per day for the restrictive
status of quetiapine would be $0.66–0.71, $1.12–1.41,
$1.67–2.26 for risperidone patient with mild moderate
and severe symptoms. CONCLUSION: To our knowl-
edge this is the first proof and practical application. Re-
strictions were removed in both provinces.
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OBJECTIVES: To develop a risk adjusted outcomes mea-
surement system that compensates for the lack of clinical
information in the claims data by dividing diseases into
different stages according to the severity at various stages
of the disease progression and the presence of other con-
ditions and procedures coded in the claims database.
METHODS: The data sources used were Medicare and
a large employer’s claims databases, which covered ap-
proximately 12 million and 130 thousand hospitali-
zations per year respectively. Rigorous data validation
processes were applied to ensure data validity. Our meth-
odology was based on the research completed by JS Gon-
nella, et.al,, (1987) “A Clinically Based Approach to
Measurement of Disease Severity”, sponsored by Na-
tional Center for Health Services Research, which classi-
fied diseases and combinations of diseases into different
stages according to severity. Our risk adjustment system
applied this approach to the principle diagnosis, second-
ary diagnoses and procedures coded in the claims data, to
derive severity measurements for each hospitalization. In
addition, we adjusted for the number of body systems in-
volved, patient age, gender and other factors. Outcomes
measurement included mortality, potentially avoidable
complications, length of hospital stay, total charges and
total cost. For each DRG group, logistic regression and
multiple regression models were developed from the
Medicare claims data to create risk adjusted norms.
Models were checked for statistical and clinical validity.
RESULTS: The model outputs were applied to the large
employer’s claims data to score each patient for each out-
come measurement. The results allowed for multi-dimen-
sional comparisons on quality measurements and re-
source utilization measurements for all the hospitals in
the large employer’s database. CONCLUSIONS: The
uniqueness of our methodology was that it adjusted for
severity of diseases at various stages and combinations of
diseases and number of body systems involved. It pro-
vided a more accurate means for risk adjustment than
currently available.
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At ISPOR’s Third Annual European Conference, we pre-
sented a new formula that can naturally extend the tradi-
tional formula for sample-size calculation of a clinical
trial, considering the cost-effectiveness ratios for two reg-
imens A and B. OBJECTIVE: According to the formula,
to explore applicability and validity of such a theoretical
framework in real clinical trials, and then show the bene-
fit which the new formula brings in terms of designing a
prospective cost-effectiveness trial. METHODS: We
searched and reviewed the published Japanese articles
these ten years that reported socioeconomic evaluation of
pharmaceuticals based on a clinical trial for two regi-
mens: a new treatment and an old one. Subsequently we
assessed the applicability and the validity of our formula
in the context of such reviewed articles, and then if the
formula could be applied, we calculated two sample
sizes: considering effect only vs. cost-effectiveness. RE-
SULTS: We reviewed eighteen Japanese articles which
conducted cost-effectiveness analysis using modeling or
retrospective cost evaluation after clinical trials except
one prospective study. Of these eight were selected as ap-
plicable for our formula. In all of them we found that the
sample size for one regimen, considering effect only vs.
cost-effectiveness, can be reduced such as 1534 to 5 at
the best, and 632 to 319 at the worst ratio. CONCLU-
SION: In the eight published Japanese studies, the sample
size of each clinical trial considering effect only could ac-
tually be reduced if such studies are to be designed in ad-
vance as a prospective cost-effectiveness trial considering
the difference of the cost-effectiveness ratios of two regi-
mens.
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